Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSD | P07339 | 2/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.49 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | TACR2 | P21452 | 2/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17305281 | 1.00 | CTSD (0.56) | CTSDPOLBDDB1CRBNTSHR | |
| SCHEMBL6970123 | 0.95 | CTSD (0.58) | CTSDPOLBDDB1CRBNTACR2 | |
| SCHEMBL23459341 | 0.95 | CTSD (0.58) | CTSDPOLBDDB1CRBNTACR2 | |
| SCHEMBL2132646 | 0.89 | CTSD (0.59) | CTSDPOLBDDB1CRBNTACR2 | |
| SCHEMBL8270781 | 0.89 | CTSD (0.59) | CTSDPOLBDDB1CRBNTACR2 | |
| SCHEMBL19419777 | 0.89 | CTSD (0.59) | CTSDPOLBDDB1CRBNTACR2 | |
| SCHEMBL5963304 | 0.83 | CTSD (0.43) | CTSD | |
| SCHEMBL76518 | 0.83 | CTSD (0.45) | CTSDPOLBDDB1CRBN | |
| SCHEMBL5966548 | 0.83 | CTSD (0.45) | CTSDPOLBCRBN | |
| SCHEMBL6977367 | 0.81 | CTSD (0.41) | CTSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240246965-A1 | NOVEL HETEROCYCLIC COMPOUNDS AND THEIR USE | EQUINORM LTD | 2024-07-25 | — | — | US | disclosed |
| EP-4313985-A2 | HETEROCYCLIC COMPOUNDS AND THEIR USE | Equinorm Ltd (FI) | 2024-02-07 | — | — | EP | disclosed |
| CN-117412975-A | Heterocyclic compounds and their use | 伊科诺姆有限公司 | 2024-01-16 | — | — | CN | disclosed |
| US-20230226035-A1 | SMALL MOLECULES AGAINST CEREBLON TO ENHANCE EFFECTOR T CELL FUNCTION | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2023-07-20 | — | — | US | disclosed |
| WO-2022207979-A2 | NOVEL HETEROCYCLIC COMPOUNDS AND THEIR USE | EQUINORM LTD (FI) | 2022-10-06 | — | — | WO | disclosed |
| WO-2017161119-A1 | SMALL MOLECULES AGAINST CEREBLON TO ENHANCE EFFECTOR T CELL FUNCTION | H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE, INC. (US) | 2017-09-21 | — | — | WO | disclosed |
| CN-1317790-C | Nonaqueous electrolyte and secondary lithium battery using the same | MITSUBISHI CHEM CORP (JP) | 2007-05-23 | — | — | CN | disclosed |
| US-20060172201-A1 | Non-aqueous electrolyte and lithium secondary battery using the same | MITSUBISHI CHEMICAL CORPORATION (JP) | 2006-08-03 | — | — | US | disclosed |
| EP-1357628-A1 | NONAQUEOUS ELECTROLYTIC LIQUIDS AND LITHIUM SECONDARY BATTERY EMPLOYING THE SAME | MITSUBISHI CHEMICAL CORPORATION (JP) | 2003-10-29 | — | — | EP | disclosed |
| CN-1411619-A | Nonaqueous electrolyte and secondary lithium battery using the same | MITSUBISHI CHEM CORP (JP) | 2003-04-16 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240246965-A1 | NOVEL HETEROCYCLIC COMPOUNDS AND THEIR USE | CNR1, CNR2, OPRK1 | CTSD 4161/4885POLB 4293/4885DDB1 4421/4885 |
| US-20230226035-A1 | SMALL MOLECULES AGAINST CEREBLON TO ENHANCE EFFECTOR T CELL FUNCTION | CD4, CRBN, GZMB | CTSD 454/4885POLB 4402/4885DDB1 3336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.